

January 6, 2014



MRI Interventions Adds Industry Veteran Maria Sainz as New Board Member

As the Company's Newest Director, Ms. Sainz Brings a Wealth of Experience From an Extensive Medical Device Career

IRVINE, Calif., Jan. 6, 2014 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) today announced that its Board of Directors has elected veteran medical device executive Maria Sainz as its newest director. Ms. Sainz's distinguished career in the medical device industry spans over 20 years, and includes 10 years as the top executive for both emerging businesses and large corporate divisions, strong commercial experience bringing therapies to market, significant international experience, and service on both public and private company boards.

Since April 2012, Ms. Sainz has served as President and CEO of CardioKinetix, Inc., a venture capital-backed medical device company based in Menlo Park, California, that is pioneering a catheter-based treatment for heart failure. Prior to her time at CardioKinetix, Ms. Sainz served as President and CEO of Concentric Medical, a commercial stage company that manufactured and marketed endovascular devices for revascularizing stroke patients. Under Ms. Sainz's leadership, Concentric Medical was acquired by Stryker Corporation in October 2011, at which time Ms. Sainz was named General Manager of the Concentric business within the Stryker Neurovascular division. Ms. Sainz also held several senior roles at Guidant Corporation, including President of the Cardiac Surgery Division, where she successfully grew the 500-employee division's annual revenue from \$90 million to \$176 million, and Vice President, Global Marketing of the Vascular Intervention Division, where she was responsible for worldwide marketing, new product and market development activities. Ms. Sainz currently serves as a director of Spectranetics, Orthofix International, and CardioKinetix. Fluent in Spanish, English and French, Ms. Sainz received her Master of International Management from The American Graduate School of International Management.

Kimble Jenkins, CEO of MRI Interventions, said, "Maria has a tremendous amount of medical device industry experience. She has led high growth, venture-backed companies as well as divisions within large corporations. With her demonstrated leadership success and operating experience, Maria's perspective will be a valuable addition to our Board, and we are extremely pleased to have her as a director."

"MRI Interventions is a unique and exciting company. The company's ClearPoint® neuro and

ClearTrace® cardiac technologies are well-positioned to bring about major change in the way the healthcare system treats patients suffering from certain neurological and cardiac diseases," commented Ms. Sainz. "I am excited to be a part of this effort, and I look forward to using my knowledge and past experience to help the company in its continued growth and leadership in this important new field of medicine."

About MRI Interventions, Inc.

Founded in 1998, MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain and heart. Utilizing a hospital's existing MRI suite, the company's FDA-cleared ClearPoint® system is designed to enable a range of minimally invasive procedures in the brain. In partnership with Siemens Healthcare, MRI Interventions is developing the ClearTrace® system to enable MRI-guided catheter ablations to treat cardiac arrhythmias, including atrial fibrillation. Building on the imaging power of MRI, the company's interventional platforms strive to improve patient care while reducing procedure costs and times. MRI Interventions is also working with Boston Scientific Corporation to incorporate its MRI-safety technologies into Boston Scientific's implantable leads for cardiac and neurological applications. For more information, please visit www.mriinterventions.com.

Forward-Looking Statements

Certain matters in this press release may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements often can be identified by words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would," or the negative of these words or other words of similar meaning. Forward-looking statements by their nature address matters that, to different degrees, are uncertain and involve risk. Uncertainties and risks may cause MRI Interventions' actual results and the timing of events to differ materially from those expressed in or implied by MRI Interventions' forward-looking statements. Particular uncertainties and risks include, among others: demand and market acceptance of our products; our ability to successfully expand our sales and marketing capabilities; our ability to successfully complete the development of, and to obtain regulatory clearance or approval for, future products, including our current product candidates; availability of third party reimbursement; the sufficiency of our cash resources to maintain planned commercialization efforts and research and development programs; future actions of the FDA or any other regulatory body that could impact product development, manufacturing or sale; our ability to protect and enforce our intellectual property rights; our dependence on collaboration partners; the impact of competitive products and pricing; and the impact of the commercial and credit environment on us and our customers and suppliers. More detailed information on these and additional factors that could affect MRI Interventions' actual results are described in MRI Interventions' filings with the Securities and Exchange Commission, including, without limitation, MRI Interventions' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2013. Except as required by law, MRI Interventions undertakes no obligation to publicly update or revise any forward-looking statements contained in this press release to reflect any change in MRI Interventions' expectations or any change in events, conditions or circumstances on which any such statements are based.

David Carlson, CFO, 901-522-9300

Source: MRI Interventions, Inc.